Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Breast cancer, early

3802 - Outcome disparities by age and 21-gene recurrence score® (RS) result in hormone receptor positive (HR+) breast cancer (BC)


07 Oct 2016


Breast cancer, early


Steven Shak


Annals of Oncology (2016) 27 (6): 43-67. 10.1093/annonc/mdw364


S. Shak1, D.P. Miller2, N. Howlader3, N. Gliner2, W. Howe4, N. Schussler4, K. Cronin3, F.L. Baehner2, L. Penberthy3, V.I. Petkov3

Author affiliations

  • 1 Translational Sciences, Genomic Health, Inc., 94063 - Redwood City/US
  • 2 Translational Sciences, Genomic Health, Inc., Redwood City/US
  • 3 Division Of Cancer Control And Population Sciences, National Cancer Institute, Rockville/US
  • 4 Analytic Services & Data Management, Information Management Systems, Inc., Calverton/US


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 3802


BC diagnoses in older patients (pts) are rising as population demographics change and life expectancy increases. The multinational TEAM study (N = 9,766) reported worse outcomes for older pts with HR+ BC (JAMA. 2012;307:590). To confirm this finding and to examine the role of tumor biology, SEER and Genomic Health collaborated to electronically supplement SEER registries with RS results and evaluate BC-specific mortality (BCSM).


21-gene RS results were provided to the NCI-sponsored SEER registries and linked to SEER BC cases. Eligible pts were diagnosed (Jan 2004 – Dec 2011) with N0 HR+ BC, and had no prior malignancy or multiple tumors. BCSM, defined previously (JNCI. 2010;102:1584), was analyzed separately for pts


Of 184,190 eligible pts, 70%/30% were  1-2 cm). Reported chemotherapy (CT) use and 5-y BCSM are shown in Table. CT use was lower for pts ≥70 y (p 


This large population-based observational study of N0 HR+ BC shows that unacceptably high BCSM persists in US clinical practice for pts ≥70 y with either no 21-gene assay done or an RS ≥18 (but not RS

Clinical trial identification


Legal entity responsible for the study

Steven Shak, Dave P. Miller, Lynne Penberthy, Valentina I. Petkov


National Cancer Institute


S. Shak, D.P. Miller, N. Gliner, F.L. Baehner: Employed by Genomic Health; stock ownership in Genomic Health. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings